You do not have uploaded videos yet.

Choose "Upload Response Video" option on left to create
new video and your response video as well.

Good Morning, It’s Tuesday January 24th, 2012, I’m Christina Collins with CRWENewswire Stocks In Action. BioLineRx Limited - symbol BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience, to develop and commercialize BL-8020, an orally available treatment...

Good Morning, It’s Tuesday January 24th, 2012, I’m Christina Collins with CRWENewswire Stocks In Action. BioLineRx Limited - symbol BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. On its Fourth quarter fiscal 2011, Polycom Incorporated - symbol PLCM - posted record consolidated net revenues of $407 million, compared to $340 million in the same period the prior year, and lastly TearLab Corporation - symbol TEAR - reported that after reviewing and accepting labeling submitted to it by the Company, the FDA has now granted Waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 for the TearLab Osmolarity System.

Thank you for joining me and have a great day! For CRWE Newswire, Stocks In Action, I’m Christina Collins

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.